Funder
Roche
Gilead UK and Ireland Corporate Contributions
Reference9 articles.
1. CLL update 2022: a continuing evolution in care;Kay;Blood Rev,2022
2. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia;Byrd;N Engl J Med,2014
3. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial;Sharman;Lancet,2020
4. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia;Seymour;N Engl J Med,2018
5. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial;Al-Sawaf;Lancet Oncol,2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献